Form 4: Allarity Therapeutics Grants RSUs to President & CDO

Allarity Therapeutics, Inc. granted 133,333 restricted stock units to President and Chief Development Officer Jeremy R. Graff, vesting over three years.

Summary

• Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc., acquired 133,333 shares of common stock.
• The acquisition occurred on January 7, 2026, at a price of $0 per share, indicating a grant of restricted stock units (RSUs).
• These RSUs were granted pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan.
• The RSUs will vest in equal one-third installments on the first, second, and third anniversary of the grant date, contingent on Mr. Graff's continued employment.
• Following this transaction, Mr. Graff beneficially owns 381,644 shares of common stock directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a key executive, which is generally viewed as a positive for executive retention and alignment of interests, but does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of restricted stock units to a key executive like the President and Chief Development Officer aligns management's interests with long-term shareholder value.
• Equity incentives are a standard practice for retaining and motivating senior leadership within the biotechnology industry.

Negatives

• The future vesting of these RSUs could lead to a minor dilutive effect on existing shareholders, although this is a common aspect of equity compensation plans.

Future Outlook

The restricted stock units granted to Jeremy R. Graff are scheduled to vest in equal one-third installments on the first, second, and third anniversaries of the January 7, 2026 grant date, subject to his continued relationship with the Issuer.

Management Comments

• Jeremy R. Graff is identified as the President and Chief Development Officer of Allarity Therapeutics, Inc.

Industry Context

Equity-based compensation, such as restricted stock units, is a prevalent practice across the biotechnology and pharmaceutical sectors. It serves as a critical tool for attracting, retaining, and incentivizing highly skilled executives in a competitive talent landscape, particularly in companies focused on long-term drug development and regulatory milestones.

Comparison to Industry Standards

• The grant of RSUs to a senior executive is consistent with compensation practices observed in comparable small to mid-cap biotechnology companies, where equity forms a significant portion of executive pay to align with long-term value creation.
• The three-year vesting schedule is a common industry standard designed to promote executive retention and focus on sustained performance.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting, but also improved alignment of executive incentives with long-term company performance.
• Employees: Reinforces the company's commitment to equity-based compensation plans for key personnel.

Next Steps

• The first tranche of the granted RSUs will vest on January 7, 2027, assuming continued employment.
• The second tranche will vest on January 7, 2028, assuming continued employment.
• The third and final tranche will vest on January 7, 2029, assuming continued employment.

Key Dates

Keywords

Allarity Therapeutics, ALLR, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Ownership, Executive Compensation, Biotechnology, SEC Form 4